← Back to Search

Monoclonal Antibodies

LY3848575 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through 142 days
Awards & highlights

Study Summary

This trial will study the safety & tolerability of a drug in healthy people; it'll also measure how the body absorbs and removes it. Open to anyone, it'll take up to 142 days.

Who is the study for?
This trial is for healthy adults who weigh at least 50 kg (110 lbs) for males, 40 kg (88 lbs) for females, and have a BMI of 18-30. Japanese participants must be first-generation with all parents and grandparents born in Japan. Participants can't join if they're in another study or were in one within the last 3 months.Check my eligibility
What is being tested?
The study tests LY3848575 given by IV or under the skin to see how safe it is and how the body handles it. It compares this new drug to a placebo over roughly five months, including screening time before starting.See study design
What are the potential side effects?
Since LY3848575 is being tested for safety, potential side effects are not yet known but will be monitored closely throughout the trial.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through 142 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through 142 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Secondary outcome measures
PK: AUC of LY3848575 When Administered SC.
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3848575 When Administered IV.

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3848575 SCExperimental Treatment1 Intervention
Multiple doses of LY3848575 administered subcutaneously (SC).
Group II: LY3848575 IVExperimental Treatment1 Intervention
Single ascending doses of LY3848575 administered intravenously (IV).
Group III: Placebo SCPlacebo Group1 Intervention
Placebo administered SC.
Group IV: Placebo IVPlacebo Group1 Intervention
Placebo administered IV.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3848575
2023
Completed Phase 1
~70

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,615 Previous Clinical Trials
3,200,994 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,344 Previous Clinical Trials
405,188 Total Patients Enrolled

Media Library

LY3848575 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05727072 — Phase 1
Healthy Subjects Research Study Groups: Placebo SC, LY3848575 SC, LY3848575 IV, Placebo IV
Healthy Subjects Clinical Trial 2023: LY3848575 Highlights & Side Effects. Trial Name: NCT05727072 — Phase 1
LY3848575 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05727072 — Phase 1
Healthy Subjects Patient Testimony for trial: Trial Name: NCT05727072 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research involve minors?

"Adults aged 18 to 65 years old are eligible for recruitment into this medical trial."

Answered by AI

Has the FDA sanctioned intravenous administration of LY3848575?

"Due to the paucity of data demonstrating its safety and efficacy, LY3848575 IV was assigned a rating of 1 on our team's scale."

Answered by AI

Are there any registration opportunities remaining for this trial?

"The details on clinicaltrials.gov reveal that this study is no longer actively seeking participants, as the last edit was made on February 5th 2023. Despite this, there are 829 other trials presently enlisting patients."

Answered by AI

Am I eligible to enroll in this experiment?

"This clinical trial requires 80 participants that are medically sound, with a body weight between 50-40 kg and BMI ranging from 18 to 30 kg/m². Additionally, for the first-generation Japanese cohort, the participant must possess an exclusive genetic heritage of Japanese origin born in Japan."

Answered by AI

Who else is applying?

What state do they live in?
California
What site did they apply to?
Anaheim Clinical Trials, LLC
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

I saw the trial online and was interested to see what it’s about while receiving income.
PatientReceived 2+ prior treatments

What questions have other patients asked about this trial?

How long do screening tests take?
PatientReceived 1 prior treatment
Recent research and studies
clinicaltrials.govStudy
A Study of LY3848575 in Healthy Participants
2023. "A Study of LY3848575 in Healthy Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05727072.
~30 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top